Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0XEXPT)
| ADC Name |
SGN-STNV
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
SGN-STNV
Click to Show/Hide
|
|||||
| Organization |
Seagen (Top20 MNC) (Originator)
|
|||||
| Drug Status |
Phase 1 (discontinued)
|
|||||
| Structure |
|
|||||
|
|
||||||
| Antibody Name |
Anti-Onco-foetal sialyl-Tn antibody
|
Antibody Info | ||||
| Antigen Name |
Onco-foetal sialyl-Tn
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Payload Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Mc-Val-Cit-PABC
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines
|
|||||
| Combination Type |
vedotin
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
| Indication | Phase 1 | Phase 2 | Phase 3 | Approved | ||
|---|---|---|---|---|---|---|
| Unspecific solid tumor |
1 Trials
|
|||||
| Oesophageal cancer |
1 Trials
|
|||||
| Gastroesophageal junction adenocarcinoma |
1 Trials
|
|||||
| Gastric cancer |
1 Trials
|
|||||
| Colorectal cancer |
1 Trials
|
|||||
| Pancreatic cancer |
1 Trials
|
|||||
| Lung cancer |
1 Trials
|
|||||
| Peritoneal cancer |
1 Trials
|
|||||
| Breast cancer |
1 Trials
|
|||||
| Ovarian cancer |
1 Trials
|
|||||
| Endometrial cancer |
1 Trials
|
|||||
| Cervical cancer |
1 Trials
|
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligible participants had advanced solid tumors (NSCLC, breast, GI, and gynecologic cancers) refractory to standard therapies, measurable disease per RECIST v1.1, and adequate organ function. Key exclusions included active CNS metastases, prior MMAE therapy, ≥Grade 2 neuropathy, or uncontrolled ≥Grade 3 infections. Biopsies were required for specific cohorts.
Click to Show/Hide
|
||||
| Administration Dosage |
Part A (dose escalation) and Part B (dose expansion) will include up to 25 and 180 patients (in up to 6 expansion cohorts), respectively.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT04665921 | Clinical Status | PHASE1 | ||
| Clinical Description | A Phase 1 Study of SGN-STNV in Advanced Solid Tumors | ||||
| Primary Endpoint |
Safety endpoints included incidence of AEs, lab abnormalities, and dose-limiting toxicities monitored up to 30-37 days post-treatment or approximately 3 years, analyzed descriptively.
|
||||
| Other Endpoint |
Efficacy measures (ORR, PFS, OS, DOR) and PK/immunogenicity parameters (AUC, Tmax, Cmax, Ctrough, ADA) were evaluated over approximately 3 years to assess treatment response and drug exposure characteristics.
|
||||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT04665921 | Clinical Status | Phase 1 | ||
| Clinical Description | A phase 1 study of SGN-STNV in advanced solid tumors. | ||||
References